Renaissance Venture Capital

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Autobooks, Inc. is a provider of integrated payment and accounting software designed specifically for small businesses, delivered through financial institutions. Founded in 2015 and based in Detroit, Michigan, the company offers a cloud-based platform that seamlessly connects bank accounts with various financial tools to enhance cash flow, streamline account reconciliation, and foster business growth. Its services include integrated payment applications such as invoicing and bill pay, merchant services, treasury products, and automated accounting solutions. By enabling financial institutions to offer these essential back-office services, Autobooks helps small businesses effectively manage their finances and improve their understanding of digital banking channels.

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Next Coast Ventures is a venture capital firm based in Austin, Texas, established in 2015. The firm focuses on investing in early-stage technology companies, particularly in 'Next Coast' markets outside the traditional coastal hubs. It targets seed-stage and growing startups in sectors such as workplace solutions, healthcare and wellness, retail, and marketplace software. Next Coast Ventures aims to partner with innovative entrepreneurs, offering not only financial support but also hands-on resources and guidance through its extensive industry network and the experience of its founders as entrepreneurs. The firm utilizes macro trends and themes to inform its investment strategy, positioning itself as a key player in fostering high-growth companies.

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

ArborMetrix, Inc. specializes in data analytics and technology solutions aimed at enhancing outcomes and advancing research within the healthcare industry. The company offers a platform that facilitates data collection and integration, performance measurement, and analytics, along with comprehensive database administration. Its solutions include EpisodeMetrix, which analyzes episode costs to help healthcare payers and providers optimize networks and manage care costs, and RegistryMetrix, designed for creating tailored clinical registries. Additionally, SurgicalMetrix provides insights into the performance of surgical groups by integrating various clinical and operational data. ArborMetrix’s offerings also encompass clinical quality improvement, patient and provider engagement, value-based reimbursement, and clinical research. The company serves a diverse range of clients, including specialty societies, medical device manufacturers, pharmaceutical companies, and health systems across the United States. Founded in 2011, ArborMetrix is headquartered in Ann Arbor, Michigan.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.